间质性肺病的治疗负担:经验与启示
本研究评估214例间质性肺病患者在引入ILD特异性治疗前后用药方案的复杂性,使用药物方案复杂性指数(MRCI)衡量。结果显示,引入治疗后MRCI总分显著增加,且接受泼尼松龙治疗的患者中88%存在至少一种可能受影响的合并症,提示需关注治疗复杂性及药物-疾病相互作用。
要点
- ILD患者基线多重用药常见,IPF组51%,炎症性ILD组63%。
- 引入ILD特异性治疗后,MRCI总分显著上升,复杂给药说明贡献最大。
- 接受泼尼松龙者88%有至少一种可能受影响的合并症,需警惕药物-疾病相互作用。
核心结论
- 不同病因的间质性肺病患者中多重用药和复杂用药方案普遍存在。
- 接受全身性皮质激素治疗的患者中潜在药物-疾病相互作用发生频率高。
研究设计与样本
- 研究纳入214例间质性肺病患者,评估人口学信息、合并症和用药情况。
- 在引入ILD特异性治疗前后审查用药清单,使用经验证的药物方案复杂性指数(MRCI)评估方案复杂性。
主要发现
- 214例患者中75例为特发性肺纤维化(IPF),其余为炎症性ILD(慢性过敏性肺炎45例;结缔组织病相关ILD 41例)。
- 基线多重用药常见:IPF组51%,炎症性ILD组63%。
- 引入ILD特异性治疗后,IPF组MRCI总分中位数从8(IQR 8-15)显著增至22.5(17.5-27.5),炎症性ILD组从14.5(IQR 8.5-21)增至21.5(16-30),P均<0.0001。
- 复杂给药说明对ILD特异性治疗的MRCI总分贡献最大。
- 接受泼尼松龙治疗的患者(n=113)中88%有至少一种可能受影响的合并症,常见包括胃肠道疾病(56%)、肥胖(37%)、骨质疏松(24%)和糖尿病(18%)。
临床怎么用
- 临床应仔细评估ILD患者的治疗复杂性和负担,尤其在使用全身性皮质激素时注意药物-疾病相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Patients with interstitial lung disease (ILD) are often prescribed disease-targeted and symptomatic therapies, both of which can cause significant treatment burden due to polypharmacy and drug-disease interactions. This study aimed to evaluate medication regimen complexity before and after introduction of ILD-specific therapies. Potential drug-disease interactions were evaluated for patients who were prescribed prednisolone. METHODS: In this study, 214 patients with ILD were assessed for demographic information, co-morbidities and medication use. Medication lists were reviewed prior to and after the introduction of ILD-specific therapies. Complexity of treatment regimen was examined using the validated Medication Regimen Complexity Index (MRCI). RESULTS: Of the 214 patients, 75 had idiopathic pulmonary fibrosis (IPF) while the rest had inflammatory ILD (chronic hypersensitivity pneumonitis: 45; connective tissue disease-related ILD: 41). Polypharmacy was common at baseline (IPF: 51%, inflammatory ILD: 63%). Following introduction of ILD-specific therapies, median total MRCI scores significantly increased from 8 (interquartile range (IQR) = 8-15) to 22.5 (17.5-27.5) and 14.5 (8.5-21) to 21.5 (16-30) for IPF and inflammatory ILD groups, respectively (P < 0.0001 for both). Complex dosing instructions contributed the most to total MRCI scores for ILD-specific therapies. Among patients receiving prednisolone (n = 113), 88% had ≥1 co-morbidity which may be impacted. Common co-morbidities included gastrointestinal diseases (56%), obesity (37%), osteoporosis (24%) and diabetes mellitus (18%). CONCLUSION: Polypharmacy and complex medication regimen are common in patients with ILD of different aetiologies. There is a high frequency of potential drug-disease interactions among patients who are prescribed systemic corticosteroids. These findings highlight the need for careful evaluation of the impact of therapeutic complexity and burden in patients with ILD.
引用
- Khor YH, Glaspole I, Goh NSL, et al. Therapeutic burden in interstitial lung disease: Lessons to learn. Respirology. 2019. PMID: 30790404. doi:10.1111/resp.13480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。